

■ **Insulin detemir appears to be more beneficial than isophane insulin suspension [NPH insulin] for paediatric patients with type 1 diabetes mellitus,** reports a multinational research group. Their randomised, open-label study* involved 347 such patients aged 6–17 years who received 26 weeks' treatment with insulin detemir (n = 232) or isophane insulin suspension, injected once or twice daily, and titrated according to fasting plasma glucose (FPG) levels. At 26 weeks, although insulin detemir recipients had similar mean HbA_{1c} levels, compared with isophane insulin recipients (8.0% and 7.9%, respectively), the insulin detemir recipients achieved significantly more favourable outcomes regarding reductions in within-subject day-to-day variation in FPG, risk of nocturnal hypoglycaemia and mean BMI Z-score.

* sponsored by Novo Nordisk A/S

Robertson KJ, et al. Insulin detemir compared with NPH insulin in children and adolescents with type 1 diabetes. *Diabetic Medicine* 24: 27-34, No. 1, Jan 2007

801063980